1 1

GPRC5D Flag&His Tag Full Length Protein, Human(Detergent)

GPRC5D Flag&His Tag Full Length Protein, Human(Detergent)

Catalog Number: UA060039 Brand: UA BIOSCIENCE
Share:
Price:
$1,075 USD
$1,075 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Accession Q9NZD1-2
Concentration 0.6 mg/mL
Amino Acid Sequence

N-terminal Flag-tagged Tyr2–Arg300 with a polyhistidine tag at the C-terminus.
Expression System HEK293
Molecular Weight 35-40 kDa (Reducing)
Purity ＞85% by SDS-PAGE
Conjugation Unconjugated
Tag His Tag, Flag Tag
Physical Appearance Liquid
Storage Buffer

25 mM Hepes, pH7.5, 150 mM NaCl, 0.0045%LMNG, 0.0015%GDN
Stability & Storage

Stable for 3 months upon stored at -80℃ from the date of receipt. And avoid repeated freeze-thaws cycles.
Reference

1. Jeong, J., et al. (2024). Structural basis for the recognition of GPRC5D by talquetamab, a bispecific antibody for multiple myeloma. Journal of Molecular Biology, 436(20), 168748.
2. Smith, E. L., et al. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746.
3. Yan, P., et al. (2024). The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer. Nature communications, 15(1), 5255.

Background

GPRC5D (G protein-coupled receptor class C group 5 member D) is an orphan Class C GPCR encoded by the GPRC5D gene on chromosome 12p13. The core transmembrane protein comprises ~308 residues, featuring a short N-terminal extracellular region (20–50 aa) and lacking the large Venus flytrap domain typical of classical Class C GPCRs.

Structurally, it forms a symmetric homodimer via TM4-TM4/5 interfaces, stabilized by cholesterol molecules. It has an unusually short ECL2, creating an exposed shallow extracellular pocket, and displays weak constitutive Gi/o activity in an inactive-like conformation.

GPRC5D is highly and specifically overexpressed on malignant plasma cells in multiple myeloma (MM), with expression independent of BCMA. High GPRC5D levels correlate with shorter progression-free survival.

Therapeutically, Talquetamab (FDA-approved bispecific GPRC5D/CD3 T-cell engager) and GPRC5D-targeted CAR-T cells have shown potent preclinical/clinical activity, with no significant on-target/off-tumor toxicity. Additionally, LM-305, a GPRC5D-targeting ADC developed by LaNova Medicines (licensed to AstraZeneca), is in Phase I/II trials for relapsed/refractory MM.

Picture

SDS-PAGE

2μg (R: reducing condition, N: non-reducing condition).

ELISA

Immobilized Human GPRC5D Protein at 5 μg/mL (100 μL/well) on Nickel coated plate can bind Anti-Human GPRC5D Antibody (LM-305 antibody), Human IgG1, with a linear range of 0.15-0.35 ng/mL.

Immobilized Human GPRC5D Protein at 2 μg/mL (100 μL/well) on Nickel coated plate can bind Talquetamab, with a linear range of 0.36-0.58 ug/mL.